Anticoagulation in adults with congenital heart disease: The who, the when and the how?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Anticoagulation in adults with congenital heart disease : The who, the when and the how? / Jensen, A S; Idorn, L; Nørager, B; Vejlstrup, N; Søndergaard, Lars.
I: Heart, Bind 101, Nr. 6, 03.2015, s. 424-9.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Anticoagulation in adults with congenital heart disease
T2 - The who, the when and the how?
AU - Jensen, A S
AU - Idorn, L
AU - Nørager, B
AU - Vejlstrup, N
AU - Søndergaard, Lars
N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
PY - 2015/3
Y1 - 2015/3
N2 - Adults with congenital heart disease are a growing population. One of the major challenges in the care of these patients is to prevent thromboembolic episodes. Despite relative young age and no typical cardiovascular risk factors, this cohort has a high prevalence of thrombotic events. It is difficult to use treatment algorithms from the general adult population with acquired heart disease in this heterogeneous population due to special conditions such as myocardial scarring after previous surgery, atypical atrial flutter, prothrombotic conditions and the presence of interatrial shunts. Furthermore, there is a lack of scientific evidence regarding how to prevent thromboembolic events with anticoagulation in adults with congenital heart disease. The aim of this paper is to review the current literature pertaining to anticoagulation in adults with congenital heart disease and hence enable recommendations for which patients are likely to benefit from which anticoagulation treatments, when they should be considered and how these would be carried out.
AB - Adults with congenital heart disease are a growing population. One of the major challenges in the care of these patients is to prevent thromboembolic episodes. Despite relative young age and no typical cardiovascular risk factors, this cohort has a high prevalence of thrombotic events. It is difficult to use treatment algorithms from the general adult population with acquired heart disease in this heterogeneous population due to special conditions such as myocardial scarring after previous surgery, atypical atrial flutter, prothrombotic conditions and the presence of interatrial shunts. Furthermore, there is a lack of scientific evidence regarding how to prevent thromboembolic events with anticoagulation in adults with congenital heart disease. The aim of this paper is to review the current literature pertaining to anticoagulation in adults with congenital heart disease and hence enable recommendations for which patients are likely to benefit from which anticoagulation treatments, when they should be considered and how these would be carried out.
KW - Adult
KW - Anticoagulants
KW - Heart Defects, Congenital
KW - Humans
KW - Practice Guidelines as Topic
KW - Thromboembolism
U2 - 10.1136/heartjnl-2014-305576
DO - 10.1136/heartjnl-2014-305576
M3 - Review
C2 - 25281599
VL - 101
SP - 424
EP - 429
JO - Heart
JF - Heart
SN - 1355-6037
IS - 6
ER -
ID: 162712192